Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

L-Carnitine and Reduced C-Reactive Protein Levels

Research synthesisHigh evidenceModerate effect7 studies · 6 beneficial · 1 neutral · 0 harmful

Across 7 studies, 6 reported beneficial effects on reducing C-reactive protein (CRP) levels, with effect sizes ranging from small to large, most commonly moderate. The most frequently studied doses were 2–3 g/day, and the median study duration was only 7 days, indicating short-term effects. Populations included clinical patients with various inflammatory conditions such as sepsis, migraine, NAFLD, and COVID-19.

  • Effective dose range: 2-3 g/day
  • Studied populations: clinical populations with various inflammatory conditions (e.g., sepsis, migraine, NAFLD, COVID-19)

Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Most studies were short-term (median 7 days) and in clinical populations with acute inflammation, limiting generalizability to long-term use or healthy individuals. The only neutral study was in NAFLD patients with a small sample size and did not reach statistical significance.

Generated Jul 15, 2026
Doses used in studies
  • mg/day: 500–3,000 (median 3,000, IQR 1,750–3,000) — 3 studies
  • g/day: 2–3 (median 2.5, IQR 2.25–2.75) — 2 studies
Time to effect
Median: 7 days · IQR 7 days–2.8 months · Range 5 days–3.7 months — Reported in 5 of 7 studies
Safety in these studies
7 of 7 papers
Back to top